ATLANTA--(BUSINESS WIRE)--MIV Therapeutics, Inc. (OTCBB:MIVI) (Frankfurt:MIV), a leading developer of next-generation coatings and advanced drug-delivery systems for cardiovascular stents and other implantable medical devices, announced that senior research analyst Kenneth Siri, CFA, of Jesup & Lamont Securities, maintained his Buy rating for MIV Therapeutics and adjusted his target price to $20.00 to reflect the Company’s recent 1-for-10 reverse stock split.
